Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
Atherosclerotic intracranial arterial stenosis (AICAS) corresponds to luminal narrowing of
the major intracranial arteries. The prevalence of intracranial atherosclerotic stenosis
accounts for 33% to 67% of stroke or transient ischemic attack (TIA) cases in China and other
countries in Asia. AICAS is also highly associated with the risk of stroke recurrence.
Possible mechanisms of cerebral infarction secondary to AICAS are likely linked with
hemodynamic compromise distal to site of stenosis.
Computed tomography perfusion (CTP) can be used to evaluate vasoreactivity and
cerebrovascular reserve in patients with AICAS and predict future stroke. The parameters of
CTP include ①cerebral blood flow(CBF),② cerebral blood volume(CBV) and ③mean transit
time(MTT). Relative regional cerebral blood flow (rCBF) was evaluated as the percentage
radioisotope counts in the region of interest (ROI) of the affected side against the
corresponding ROI in the unaffected contralateral side.
Statins can decrease the incidence of transient ischemic attack or ischemic stroke and
improve stroke outcome. Few studies focus on the relationship between statins therapy and
cerebral perfusion.
Whether intensive rosuvastatin therapy compared with standard rosuvastatin therapy can
improve hemodynamic situation and cerebral perfusion status in AICAS has not been
illustrated.
Based on those studies, the investigators hypothesized that intensive rosuvastatin may also
improve the symptoms of AICAS not only through enhancing the stability of atherosclerotic
plaques, but also its pleiotropic effects. So it can change the hemodynamic status around the
plaque and increase cerebral flow in the downstream territory. So in this study the
investigators try to analysis statin's impact on the hemodynamic changes as well as the
downstream perfusion which is determined by CTP.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University